Non-alcoholic fatty liver disease and vascular disease
File(s)
Author(s)
Type
Journal Article
Abstract
Non-Alcoholic Fatty Liver Disease (NAFLD) represents an increasing cause of liver disease worldwide. However, notably, the primary cause of morbidity and mortality in patients with NAFLD is cardiovascular disease (CVD), with fibrosis stage being the strongest disease-specific predictor. It is globally-projected that NAFLD will become increasingly prevalent, especially among children and younger adults. As such, even within the next few years, NAFLD will contribute considerably to the overall CVD burden.
In this review, we discuss the role of NAFLD as an emerging risk factor for CVD. In particular, this article aims to provide an overview of pathological drivers of vascular damage in patients with NAFLD. Moreover, the impact of NAFLD on the development, severity and the progression of subclinical and clinical CVD will be discussed. Finally, the review illustrates current and potential future perspectives for screening for CVD in this high-risk population.
In this review, we discuss the role of NAFLD as an emerging risk factor for CVD. In particular, this article aims to provide an overview of pathological drivers of vascular damage in patients with NAFLD. Moreover, the impact of NAFLD on the development, severity and the progression of subclinical and clinical CVD will be discussed. Finally, the review illustrates current and potential future perspectives for screening for CVD in this high-risk population.
Date Issued
2020-03-17
Date Acceptance
2019-06-07
Citation
Current Vascular Pharmacology, 2020, 18 (1)
ISSN
1570-1611
Publisher
Bentham Science Publishers
Journal / Book Title
Current Vascular Pharmacology
Volume
18
Issue
1
Copyright Statement
© 2019 Bentham Science Publishers.
Sponsor
Medical Research Council
Medical Research Council (MRC)
Identifier
https://www.eurekaselect.com/180328/article
Grant Number
MR/R00875/1
MR/R000875/1
Subjects
Cardiovascular Disease
Cardiovascular risk
Non-Alcoholic Fatty Liver Disease
atherosclerosis.
endothelial dysfunction
1115 Pharmacology and Pharmaceutical Sciences
Cardiovascular System & Hematology
Publication Status
Published
Date Publish Online
2020-03-17